Drug-induced extrapyramidal syndromes.
D000367:Age Factors; D014150:Antipsychotic Agents / Q000009:adverse effects; D001480:Basal Ganglia Diseases / Q000139:chemically induced* / Q000503:physiopathology / Q000517:prevention & control; D000697:Central Nervous System Stimulants / Q000627:therapeutic use; D002648:Child; D003937:Diagnosis, Differential; D004305:Dose-Response Relationship, Drug; D004422:Dystonia Musculorum Deformans / Q000139:chemically induced / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control; D005260:Female; D006801:Humans; D008297:Male; D009069:Movement Disorders / Q000139:chemically induced / Q000517:prevention & control; D010276:Parasympatholytics / Q000627:therapeutic use; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control; D010640:Phenothiazines; D012737:Sex Factors; D014149:Tranquilizing Agents / Q000009:adverse effects*
D014150:Antipsychotic Agents; D000697:Central Nervous System Stimulants; D010276:Parasympatholytics; D010640:Phenothiazines; D014149:Tranquilizing Agents